ZCA
AGIO icon

Zeke Capital Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Zeke Capital Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,125
Closed -$405K – 550
2019
Q2 		$405K Buy
8,125
+1,400
+21% +$74.8K 0.04% 401
2019
Q1 		$454K Buy
+6,725
New +$392K 0.04% 382

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Zeke Capital Advisors's AGIO Position: Q3 2019 in Review

Zeke Capital Advisors sold out of Agios Pharmaceuticals (AGIO) in Q3 2019, closing a stake of 8,125 shares — an estimated $405K sold.

Zeke Capital Advisors first reported a position in AGIO in Q1 2019 and held it in 2 quarters. The position peaked at $454K in Q1 2019. 189 funds tracked by Wall St. Rank hold AGIO as of Q3 2019.

  • Zeke Capital Advisors reported no remaining Agios Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Zeke Capital Advisors sold 8,125 Agios Pharmaceuticals shares in Q3 2019, an estimated $405K.
  • Zeke Capital Advisors first reported a position in Agios Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Zeke Capital Advisors's Agios Pharmaceuticals position peaked at $454K in Q1 2019.
  • 189 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2019.

Based on Zeke Capital Advisors's 13F filing for Q3 2019, filed 18 Oct 2019.